Di Song1,2,3, Xiao-Rong Liu4, Zhi Chen5, Hui-Jie Xiao6, Jie Ding6, Shu-Zhen Sun7, Hong-Yan Liu8, Wei-Yi Guo1,2,3, Su-Xia Wang1,2,3, Feng Yu9,10,11,12, Ming-Hui Zhao1,2,3,13. 1. Renal Division, Department of Medicine, Peking University Institute of Nephrology, Peking University First Hospital, Beijing, People's Republic of China. 2. Key laboratory of Renal Disease, Ministry of Health of China, Beijing, People's Republic of China. 3. Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China, Beijing, 100034, People's Republic of China. 4. Department of Nephrology, Beijing Children's Hospital affiliated to Capital Medical University, West District Nan Li Shi Lu 56th, Beijing, 100045, People's Republic of China. desin2000@sina.com. 5. Department of Nephrology, Beijing Children's Hospital affiliated to Capital Medical University, West District Nan Li Shi Lu 56th, Beijing, 100045, People's Republic of China. 6. Department of Pediatrics, Peking University First Hospital, Beijing, People's Republic of China. 7. Department of Pediatrics, Shandong Provincial Hospital affiliated with Shandong University, Jinan, People's Republic of China. 8. Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China. 9. Renal Division, Department of Medicine, Peking University Institute of Nephrology, Peking University First Hospital, Beijing, People's Republic of China. yufengevert1@sina.com. 10. Key laboratory of Renal Disease, Ministry of Health of China, Beijing, People's Republic of China. yufengevert1@sina.com. 11. Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China, Beijing, 100034, People's Republic of China. yufengevert1@sina.com. 12. Department of Nephrology, Peking University International Hospital, Beijing, 102206, People's Republic of China. yufengevert1@sina.com. 13. Peking-Tsinghua Center for Life Sciences, Beijing, People's Republic of China.
Abstract
BACKGROUND: Anti-complement factor H (CFH) autoantibody-associated hemolytic uremic syndrome (HUS) is a severe sub-type of HUS. METHODS: We assessed the clinical and renal pathological features, circulating complement levels, and genetic background of Chinese pediatric patients with this sub-type of HUS. Thirty-three consecutive patients with acute kidney injury who tested positive for serum anti-CFH autoantibodies were enrolled in this study. RESULTS: All of the eight patients who underwent renal biopsies presented with changes typical of thrombotic microangiopathy, especially changes in chronic characteristics. Compared to patients in remission and normal control subjects, patients with acute disease had significantly lower plasma CFH levels and significantly higher plasma complement 3a (C3a), C5a, and terminal complement complex (SC5b-9) levels. The CFH-anti-CFH immunoglobin G (IgG) circulating immunocomplex (CFH-CIC) titers were more closely correlated with CFH plasma levels than anti-CFH IgG levels. Of the 22 patients, four (18%) were homozygous for CFHR3-1Δ and ten were heterozygous for CFHR1 or CFHR3 deletions. Most patients responded well to a combination of plasma and immunosuppressive therapies, with a remission rate of 87%. At the end of the follow-up, nine patients reached the combined end-points, including two with end-stage renal disease and seven with relapses. CONCLUSION: Plasma C3a, C5a, and SC5b-9 levels predicted disease activity in anti-CFH autoantibody-associated HUS patients enrolled in this study. These patients responded well to plasma therapy combined with immunosuppression.
BACKGROUND:Anti-complement factor H (CFH) autoantibody-associated hemolytic uremic syndrome (HUS) is a severe sub-type of HUS. METHODS: We assessed the clinical and renal pathological features, circulating complement levels, and genetic background of Chinese pediatric patients with this sub-type of HUS. Thirty-three consecutive patients with acute kidney injury who tested positive for serum anti-CFH autoantibodies were enrolled in this study. RESULTS: All of the eight patients who underwent renal biopsies presented with changes typical of thrombotic microangiopathy, especially changes in chronic characteristics. Compared to patients in remission and normal control subjects, patients with acute disease had significantly lower plasma CFH levels and significantly higher plasma complement 3a (C3a), C5a, and terminal complement complex (SC5b-9) levels. The CFH-anti-CFH immunoglobin G (IgG) circulating immunocomplex (CFH-CIC) titers were more closely correlated with CFH plasma levels than anti-CFH IgG levels. Of the 22 patients, four (18%) were homozygous for CFHR3-1Δ and ten were heterozygous for CFHR1 or CFHR3 deletions. Most patients responded well to a combination of plasma and immunosuppressive therapies, with a remission rate of 87%. At the end of the follow-up, nine patients reached the combined end-points, including two with end-stage renal disease and seven with relapses. CONCLUSION: Plasma C3a, C5a, and SC5b-9 levels predicted disease activity in anti-CFH autoantibody-associated HUSpatients enrolled in this study. These patients responded well to plasma therapy combined with immunosuppression.
Authors: Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi Journal: Clin J Am Soc Nephrol Date: 2010-07-01 Impact factor: 8.237
Authors: Stefanie Strobel; Peter F Hoyer; Christoph J Mache; Endre Sulyok; Wei-Shih Liu; Heiko Richter; Martin Oppermann; Peter F Zipfel; Mihály Józsi Journal: Nephrol Dial Transplant Date: 2009-08-07 Impact factor: 5.992
Authors: Lianne M Geerdink; Dineke Westra; Joanna A E van Wijk; Eiske M Dorresteijn; Marc R Lilien; Jean-Claude Davin; Martin Kömhoff; Koen Van Hoeck; Amerins van der Vlugt; Lambertus P van den Heuvel; Nicole C A J van de Kar Journal: Pediatr Nephrol Date: 2012-03-13 Impact factor: 3.714
Authors: Peter F Zipfel; Matthew Edey; Stefan Heinen; Mihály Józsi; Heiko Richter; Joachim Misselwitz; Bernd Hoppe; Danny Routledge; Lisa Strain; Anne E Hughes; Judith A Goodship; Christoph Licht; Timothy H J Goodship; Christine Skerka Journal: PLoS Genet Date: 2007-02-01 Impact factor: 5.917